These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic approach to multiple sclerosis by novel oral drug. Jadidi-Niaragh F; Mirshafiey A Recent Pat Inflamm Allergy Drug Discov; 2011 Jan; 5(1):66-80. PubMed ID: 21184668 [TBL] [Abstract][Full Text] [Related]
8. Drugs: An injection of hope. Graham-Rowe D Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505 [No Abstract] [Full Text] [Related]
9. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574 [TBL] [Abstract][Full Text] [Related]
12. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Gasperini C; Ruggieri S Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218 [TBL] [Abstract][Full Text] [Related]
13. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
14. New drugs may improve, complicate treatment for multiple sclerosis. Link H; Martin R Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513 [No Abstract] [Full Text] [Related]
15. Trial watch: Phase III promise for oral multiple sclerosis therapy. Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099 [No Abstract] [Full Text] [Related]
16. Emerging oral agents for multiple sclerosis. Fox EJ Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946 [TBL] [Abstract][Full Text] [Related]
17. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. Gold R CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693 [TBL] [Abstract][Full Text] [Related]
18. Oral Therapies for Multiple Sclerosis. Faissner S; Gold R Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302 [TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis. Filippi M Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650 [No Abstract] [Full Text] [Related]
20. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. Klatt J; Hartung HP; Hohlfeld R Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]